drugset / Trial / NCT03024034
A Phase 1 TP-271 Oral PK Single Ascending Dose Study
Phase 1
Completed
56 enrolled
Tetraphase Pharmaceuticals, Inc
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this study is to determine the safety and tolerability of up to 6 different single ascending oral doses of TP-271, ranging from 25 mg to 300 mg, in healthy adult male or female subjects.
Timeline
- Start
- 2017-03-02
- Primary completion
- 2017-12-01
- Completion
- 2018-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TP-271 | Small molecule | 25 mg | Oral |
| Comparator | TP-271 | Small molecule | 50 mg | Oral |
| Comparator | TP-271 | Small molecule | 100 mg | Oral |
| Comparator | TP-271 | Small molecule | 150 mg | Oral |
| Comparator | TP-271 | Small molecule | 200 mg | Oral |
| Comparator | TP-271 | Small molecule | 300 mg | Oral |
| Subject | ethylenediaminetetraacetic acid | Unknown | 250 mg | — |